Dinutuximab beta-related severe neurotoxicity: Resolution with the use of plasmapheresis

Pediatr Blood Cancer. 2022 Apr;69(4):e29465. doi: 10.1002/pbc.29465. Epub 2021 Dec 16.

Authors

Vassilios Papadakis¹, Charikleia Kelaidi¹, Kalliopi Zisaki², Kondylia Antoniadi¹, Georgios Pitsoulakis³, Sophia Polychronopoulou¹

Affiliations

¹ Department of Pediatric Hematology-Oncology, Aghia Sophia Children's Hospital, Athens, Greece.
² Department of Blood Banking, Aghia Sophia Children's Hospital, Athens, Greece.
³ Department of Tomography Imaging, Aghia Sophia Children's Hospital, Athens, Greece.

PMID: 34913569
DOI: 10.1002/pbc.29465

No abstract available

Keywords: child; dinutuximab; neuroblastoma; neurotoxicity; plasmapheresis.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal*
Humans
Neuroblastoma*
Plasmapheresis

Substances

Antibodies, Monoclonal
dinutuximab